The CAPRI trial is evaluating the ATR inhibitor, ceralasertib (AZD6738), in combination with olaparib, for platinum-sensitive or platinum-resistant recurrent ovarian cancer (NCT03462342). This evidence concerns the gene ATR and ovarian carcinoma.